A Study of ARRY-502 in Patients With Persistent Asthma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the
effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent
asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the
US will be enrolled in this study.